Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology

Annals of Oncology

Volumn 22, Issue 8, 2011, Pages 1717-1725

  Glimelius, B ^a,b   Lahn, M ^c  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

New molecular entities; Safety monitoring; Systematic review; Window trial

Indexed keywords

AMONAFIDE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; ELSAMICIN A; ENZASTAURIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IMATINIB; IPROPLATIN; IRINOTECAN; MELPHALAN; MENOGARIL; PACLITAXEL; PROCARBAZINE; RITUXIMAB; SORAFENIB; TEMSIROLIMUS; TOPOTECAN; TRIMETREXATE; UNINDEXED DRUG; VINCRISTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHILDHOOD CANCER; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; GLIOMA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDULLOBLASTOMA; MONOTHERAPY; NEUROBLASTOMA; ONCOLOGY; OSTEOSARCOMA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; SOLID TUMOR; SYSTEMATIC REVIEW;

EID: 79960975329     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq622     Document Type: Review

References (84)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-715.
2. Orloff J, Douglas F, Pinheiro J et al. The future of drug development: advancing clinical trial design. Nat Rev Drug Discov 2009; 8: 949-957.
3. Michaelis LC, Ratain MJ. Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties. Clin Cancer Res 2007; 13: 2400-2405.
4. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer 2009; 45: 275-280.
5. Eisenhauer EA, O'Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000; 18: 684-692.
6. Henderson IC. Window of opportunity. J Natl Cancer Inst 1991; 83: 894-896.
7. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
8. Gomez HL, Santillana SL, Vallejos CS et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006; 12: 832-838.
9. Guix M, Granja Nde M, Meszoely I et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 2008; 26: 897-906.
10. Mohsin SK, Weiss HL, Gutierrez MC et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005; 23: 2460-2468.
11. Carpenter P, White L, McCowage GB et al. A dose-intensive, cyclophosphamidebased regimen for the treatment of recurrent/Progressive or advanced solid tumors of childhood. Cancer 1997; 80: 489-496.
12. Horowitz ME, Etcubanas E, Christensen ML et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 1988; 6: 308-314.
13. Pappo AS, Lyden E, Breneman J et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. J Clin Oncol 2001; 19: 213-219.
14. Sandler E, Lyden E, Ruymann F et al. Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med Pediatr Oncol 2001; 37: 442-448.
15. Breitfeld PP, Lyden E, Beverly Raney R et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 2001; 23: 225-233.
16. Walterhouse DO, Lyden ER, Breitfeld PP et al. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study. J Clin Oncol 2004; 22: 1398-1403.
17. Pappo AS, Lyden E, Breitfeld P et al. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group. J Clin Oncol 2007; 25: 362-369.
18. Castleberry RP, Cantor AB, Green AA et al. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1994; 12: 1616-1620.
19. Kretschmar CS, Kletzel M, Murray K et al. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. J Clin Oncol 2004; 22: 4119-4126.
20. Stewart CF, Iacono LC, Chintagumpala M et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004; 22: 3357-3365.
21. Chintagumpala M, Friedman H, Stewart C et al. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neuro Oncol 2006; 77: 193-198.
22. Seibel NL, Krailo M, Chen Z et al. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma. Cancer 2007; 109: 1646-1653.
23. Meinhardt A, Burkhardt B, Zimmermann M et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol 2010; 28: 3115-3121.
24. Sledge GW Jr, Loehrer PJ Sr, Roth BJ, Einhorn LH. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 1988; 6: 1811-1814.
25. Kolaric K, Vukas D. Carboplatin activity in untreated metastatic breast cancer patients-results of a phase II study. Cancer Chemother Pharmacol 1991; 27: 409-412.
26. Costanza ME, Weiss RB, Henderson IC et al. Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study-Cancer and Leukemia Group B 8642. J Clin Oncol 1999; 17: 1397-1406.
27. Blackstein M, Eisenhauer EA, Wierzbicki R, Yoshida S. Epirubicin in extensive small-cell lung cancer: a phase II study in previously untreated patients: a National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 1990; 8: 385-389.
28. Slevin ML, Clark PI, Joel SP et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333-1340.
29. Clark PI, Slevin ML, Joel SP et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994; 12: 1427-1435.
30. Ettinger DS, Finkelstein DM, Abeloff MD et al. Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study. J Natl Cancer Inst 1992; 84: 1077-1084.
31. Johnson BE, Fischer T, Fischer B et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res 2003; 9: 5880-5887.
32. Adjei AA, Molina JR, Hillman SL et al. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 2007; 25: (Abstr 7547).
33. Molina JR, Mandrekar SJ, Rowland K et al. A phase II NCCTG "Window of Opportunity Front-line" study of the mTOR Inhibitor, given as a single agent in patients with advanced NSCLC: D7-07. In Oncology JoT (ed) World Conference on Lung Cancer, Edition Proffered Paper Abstracts: Session D7: Novel Therapeutics II, Thursday, September 6: Novel Therapeutics II, Thu, 12: 30-14:15. 2007. p. S413. International Association for the Study of Lung Cancer.
34. Gridelli C, Ciardiello F, Feld R et al. International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): the TORCH trial. J Clin Oncol 2010; 28: 15s (Abstr 7508).
35. Glimelius B, Lahn M, Gawande S et al. A window of opportunity phase II study of enzastaurin in chemonaive patients with asymptomatic metastatic colorectal cancer. Ann Oncol 2010; 21: 1020-1026.
36. Tabernero J, Ciardiello F, Rivera F et al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann Oncol 2010; 21: 1537-1545.
37. Pessino A, Artale S, Sciallero S et al. First-line single-agent cetuximab in patients with advanced colorectal cancer. Ann Oncol 2008; 19: 711-716.
38. Gore SD, Rowinsky EK, Miller CB et al. A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin Cancer Res 1998; 4: 2677-2689.
39. Meresse V, Vassal G, Michon J et al. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1993; 11: 630-637.
40. Valteau-Couanet D, Michon J, Boneu A et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol 2005; 23: 532-540.
41. Kager L, Zoubek A, Potschger U et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21: 2011-2018.
42. Ferguson WS, Harris MB, Goorin AM et al. Presurgical window of carboplatin and surgery and multidrug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: pediatric oncology group trial. J Pediatr Hematol Oncol 2001; 23: 340-348.
43. Bellaton E, Bertozzi AI, Behar C et al. Neoadjuvant chemotherapy for extensive unilateral retinoblastoma. Br J Ophthalmol 2003; 87: 327-329.
44. Meyer WH, Pratt CB, Poquette CA et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude children's research hospital OS-91 trial. J Clin Oncol 2001; 19: 171-182.
45. Chantada GL, Fandino A, Mato G, Casak S. Phase II window of idarubicin in children with extraocular retinoblastoma. J Clin Oncol 1999; 17: 1847-1850.
46. Busse D, Busch FW, Bohnenstengel F et al. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol 1997; 15: 1885-1896.
47. Breitfeld PP, Meyer WH. Rhabdomyosarcoma: new windows of opportunity. The Oncologist 2005; 10: 518-527.
48. Lager JJ, Lyden ER, Anderson JR et al. Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J Clin Oncol 2006; 24: 3415-3422.
49. Mantadakis E, Herrera L, Leavey PJ et al. Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study. J Clin Oncol 2000; 18: 2576-2581.
50. United States NCI. Cancer Therapy Evaluation Program: Policies, Guidelines and Procedures. Phase II Window Studies in Pediatric Oncology Meeting Report 1997; http://ctep.cancer.gov/investigatorResources/childhood_cancer/phase2.htm (10 February 2010, date last accessed).
51. Zage PE, Kletzel M, Murray K et al. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2008; 51: 747-753.
52. Carbone PP, Bauer M, Band P, Tormey D. Chemotherapy of disseminated breast cancer. Current status and prospects. Cancer 1977; 39: 2916-2922.
53. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
54. Gridelli C, Ardizzoni A, Douillard JY et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 2010; 68: 319-361.
55. Azzoli CG, Baker S Jr, Temin S et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
56. Katzel J, Fanucchi M, Li Z. Recent advances of novel targeted therapy in nonsmall cell lung cancer. J Hematol Oncol 2009; 2: 2.
57. Lynch TJ, Bogart JA, Curran WJ et al. Early stage lung cancer: new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res 2005; 11: 4981s-4983s.
58. Pallis AG, Serfass L, Dziadziuszko R et al. Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer 2009; 45: 2473-2487.
59. Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016.
60. Group NGTAT. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 1992; 10: 904-911.
61. Ackland SP, Jones M, Tu D et al. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. Brit J Cancer 2005; 93: 1236-1243.
62. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152.
63. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142.
64. Carducci MA, Musib L, Kies MS et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006; 24: 4092-4099.
65. Glimelius B, Spindler KL, Frödin J-E et al. Long-term follow-up of chemonaive patients with asymptomatic metastatic colorectal cancer treated with enzastaurin in a window of opportunity phase II study. Ann Oncol 2009; 21: 1127-1128.
66. Golfinopoulos V, Salanti G, Pavlidis N, Ioannidis JP. Survival and diseaseprogression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 2007; 8: 898-911.
67. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
68. Mancl EE, Kolesar JM, Vermeulen LC. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors. Amer J Health-System Pharm 2009; 66: 2105-2112.
69. Chang MN, Devidas M, Anderson J. One- and two-stage designs for phase II window studies. Stats in Med 2007; 26: 2604-2614.
70. Zee B, Melnychuk D, Dancey J, Eisenhauer E. Multinomial phase II cancer trials incorporating response and early progression. J Biopharm Stat 1999; 9: 351-363.
71. Frei E. Therapeutic innovation: the up-front window. Clin Cancer Res 1998; 4: 2573-2575.
72. Wells RJ. Phase II window therapy. J Clin Oncol 1995; 13: 302-303.
73. Spunt SL, Pappo AS. Cyclophosphamide and etoposide for pediatric solid tumors. J Clin Oncol 2000; 18: 3741-3743.
74. Ratain MJ, Mick R, Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 1993; 85: 1637-1643.
75. Fletcher JW, Djulbegovic B, Soares HP et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008; 49: 480-508.
76. Dancey JE, Dobbin KK, Groshen S et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010; 16: 1745-1755.
77. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327.
78. Bystrom P, Berglund A, Garske U et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer. Ann Oncol 2009; 20: 1057-1061.
79. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009; 27: 2874-2880.
80. Yu RX, Holmgren E. Endpoints for agents that slow tumor growth. Contemp Clin Trials 2007; 28: 18-24.
81. Watkins V, Hong S, Lin BK. Enzastaurin safety review: data from phase I and phase II. trials. J Clin Oncol 2006; 24: (Abstr 13077).
82. Philip PA, Mooney M, Jaffe D et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 2009; 27: 5660-5669.
83. Booth B, Glassman R, Ma P. Oncology's trials. Nat Rev Drug Discov 2003; 2: 609-610.
84. Ratain MJ. Bar the windows but open the door to randomization. J Clin Oncol 2010; 28: 3104-3106.